Efficacy and Tolerability of Pharmacotherapy Options for the Treatment of Medullary Thyroid Cancer

Metastatic and unresectable medullary thyroid carcinoma (MTC) is often difficult to treat as it is relatively unresponsive to radiation and conventional chemotherapy. This emphasizes the importance of the development of targeted therapies for advanced MTC. Vandetanib was approved by the US Food and...

Descripción completa

Detalles Bibliográficos
Autores principales: Deshpande, H. A., Sheth, K., Sosa, J. A., Roman, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Libertas Academica 2012
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3489097/
https://www.ncbi.nlm.nih.gov/pubmed/23133319
http://dx.doi.org/10.4137/CMO.S8305
_version_ 1782248717769768960
author Deshpande, H. A.
Sheth, K.
Sosa, J. A.
Roman, S.
author_facet Deshpande, H. A.
Sheth, K.
Sosa, J. A.
Roman, S.
author_sort Deshpande, H. A.
collection PubMed
description Metastatic and unresectable medullary thyroid carcinoma (MTC) is often difficult to treat as it is relatively unresponsive to radiation and conventional chemotherapy. This emphasizes the importance of the development of targeted therapies for advanced MTC. Vandetanib was approved by the US Food and Drug Administration for the treatment of symptomatic or progressive MTC in patients with advanced disease in April 2011. This therapy proved to be a breakthrough in the management of MTC. We review the efficacy and safety of this novel treatment and other treatments that are being evaluated in this disease.
format Online
Article
Text
id pubmed-3489097
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Libertas Academica
record_format MEDLINE/PubMed
spelling pubmed-34890972012-11-06 Efficacy and Tolerability of Pharmacotherapy Options for the Treatment of Medullary Thyroid Cancer Deshpande, H. A. Sheth, K. Sosa, J. A. Roman, S. Clin Med Insights Oncol Review Metastatic and unresectable medullary thyroid carcinoma (MTC) is often difficult to treat as it is relatively unresponsive to radiation and conventional chemotherapy. This emphasizes the importance of the development of targeted therapies for advanced MTC. Vandetanib was approved by the US Food and Drug Administration for the treatment of symptomatic or progressive MTC in patients with advanced disease in April 2011. This therapy proved to be a breakthrough in the management of MTC. We review the efficacy and safety of this novel treatment and other treatments that are being evaluated in this disease. Libertas Academica 2012-10-31 /pmc/articles/PMC3489097/ /pubmed/23133319 http://dx.doi.org/10.4137/CMO.S8305 Text en © 2012 the author(s), publisher and licensee Libertas Academica Ltd. This is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited.
spellingShingle Review
Deshpande, H. A.
Sheth, K.
Sosa, J. A.
Roman, S.
Efficacy and Tolerability of Pharmacotherapy Options for the Treatment of Medullary Thyroid Cancer
title Efficacy and Tolerability of Pharmacotherapy Options for the Treatment of Medullary Thyroid Cancer
title_full Efficacy and Tolerability of Pharmacotherapy Options for the Treatment of Medullary Thyroid Cancer
title_fullStr Efficacy and Tolerability of Pharmacotherapy Options for the Treatment of Medullary Thyroid Cancer
title_full_unstemmed Efficacy and Tolerability of Pharmacotherapy Options for the Treatment of Medullary Thyroid Cancer
title_short Efficacy and Tolerability of Pharmacotherapy Options for the Treatment of Medullary Thyroid Cancer
title_sort efficacy and tolerability of pharmacotherapy options for the treatment of medullary thyroid cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3489097/
https://www.ncbi.nlm.nih.gov/pubmed/23133319
http://dx.doi.org/10.4137/CMO.S8305
work_keys_str_mv AT deshpandeha efficacyandtolerabilityofpharmacotherapyoptionsforthetreatmentofmedullarythyroidcancer
AT shethk efficacyandtolerabilityofpharmacotherapyoptionsforthetreatmentofmedullarythyroidcancer
AT sosaja efficacyandtolerabilityofpharmacotherapyoptionsforthetreatmentofmedullarythyroidcancer
AT romans efficacyandtolerabilityofpharmacotherapyoptionsforthetreatmentofmedullarythyroidcancer

Ejemplares similares